NB1011

NB1011 is a nucleoside analogue that was developed as a potential anticancer agent. It was originally developed by Nuvelo, but the development was discontinued after Phase II clinical trials.

History

NB1011 was first developed by Nuvelo, a biopharmaceutical company based in San Carlos, California. The drug was designed as a nucleoside analogue, a type of drug that is often used in the treatment of cancer.

Mechanism of Action

NB1011 works by being converted into a toxic metabolite by the enzyme thymidylate synthase (TS). This enzyme is often overexpressed in cancer cells, making them particularly susceptible to the effects of NB1011. The toxic metabolite then interferes with the DNA replication process, causing the cancer cells to die.

Clinical Trials

NB1011 entered Phase I clinical trials in 2000. The results of these trials, published in 2003, showed that the drug was well tolerated and had some anticancer activity. The drug then entered Phase II clinical trials, which were completed in 2005. However, the results of these trials were disappointing, and Nuvelo decided to discontinue the development of NB1011.

Future Prospects

Despite the discontinuation of NB1011, research into nucleoside analogues continues. These drugs have the potential to be effective anticancer agents, particularly in cancers that overexpress TS. Future research will likely focus on improving the efficacy and reducing the side effects of these drugs.

See Also

• Nucleoside analogue
• Anticancer drug
• Thymidylate synthase
• Clinical trial

NB1011 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia